An influence of selective pressure of antibiotics on gram-negative bacterial flora resistance in the haematology unit at the Teaching Hospital Hradec Kralove, Czech Republic;Vliv selekčního tlaku vybraných antibiotik na rezistenci nejčastěji se vyskytujících gramnegativních bakteriálních kmenů na oddělení klinické hematologie ve Fakultní Nemocnici v Hradci Králové

Klinicka Onkologie

Volumn 18, Issue 4, 2005, Pages 138-144

  Zemkova M ^a   Jebavy L ^b   Cermak P ^b   Koblihova H ^a   Vlcek J ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

Antibiotic selective pressure; Antibiotics; Gram negative bacteria; Haemato oncology

Indexed keywords

EID: 77349105325     PISSN: 0862495X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Urli T, Perone G, Acquarolo A, Zappa S, Antonini B. Surveillance of infections acquired in intensive care: usefulness in clinical practice. J Hosp Infect 2002; 52: 130-135
2. Leverstein-van Hall MA, Fluit AC et al. Control of nosocomial multiresistant Enterobacteiaceae using temporary restrictive- antibiotic agent policy. Eur J Clin Microbiol Infect Dis 2000; 20: 785-791
3. Kolář M. Antibiotická léčba nozokomiálních infekcí. Triton; Praha 2000
4. Urbášková P. Rezistence bakterií k antibiotikům. Vybrané metody. Triton; Praha 1999
5. Garouste- Orgeas M, Marie O, Rouveau M, Villers S, Arlet G, Schlemmer B: Secondary carriage with multi-resistant Acinetobacter spp. and Klebsiella pneumoniae in an adult ICU population: relationship with nosocomial infections and mortality. J Hosp Infect 1996; 34: 279-289.
6. Raymond DP, Pelletier SJ,Crabtree TD, Evans HL, Pruet TL, Sawyer RG.Impact of antibiotic-resistant Gram-negative bacilli infections on outcome in hospitalized patients. Crit Care Med 2003; 31: 1035-1041
7. Waterer GW, Wundering RG.: Increasing threat of Gram-negative bacteria. Crit Care Med 2001; 29: 75-81
8. Kolář M, Kurašová Y, Látal T, Hejnar P, Faber E, Raida L. Výskyt bakteriálních kmenů izolovaných u neutropenických pacientů a jejich rezistence k antibiotikům. Čas Lék čes 1998; 137: 84-88
9. Mayer J. Infekce způsobené grampozitivními baktériemi u onkologicky nemocných a význam vankomycinu v jejich léčbě. Klin onkol 1998; 11:137-143
10. EORTC- International Antimicrobial Therapy Cooperative Group.Three antibiotic regimens in the treatment of infections in febrile granulocytopenic patients with cancer. Am J Med 1989; 86: 668-672
11. Nyč O, Kavan P, Lochmann O. Současné možnosti antimikrobní léčby onkologicky nemocného pacienta s febrilní neutropenií. Remedia Klin. Mikrobiol 1997; 1: 144-147
12. National Commitee for Clinical Laboratory Standards.Performance standards for amtimicrobial susceptibility testing. Sixth international supplement, Nat Comm Clin Lab Standards, Villanova PA, 1995
13. Anatomical therapeutic chemical (ATC) index (including defined daily doses (DDDs) for plain substances) Oslo: WHO collaboration centre for drug statistics methodology, 1996
14. Bergman U, Christerson I, Jansson B, Wiholm BE. Auditing drug utilization by means of defined daily dose per bed-day. A methodological study, Eur J Clin Pharmacol 1980; 17: 183-187
15. Vlček J, Pozlerová E, Lonská V et al. Analýza vývoje rezistence gramnegativních tyček k fluorochinolonům, amikacinu a třetí generaci cefalosporinů ve vztahu k jejich spotřebě ve fakultní nemocnici. Remed Klin Mikrobiol 1997; 1 (6): 176-180
16. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum betalactamase producing Escherichia coli and Klebsiella pneumonie: risk factors for infection and impact of resistence on outcomes. Clin Infect Dis 2001; 32: 1162-1171
17. Lautenbach E, Strom BL, Bilker WB, Patel JB, Edelstein PH, Fishman NO. Epidemiological investigation of fluoroquinolone resistence in infections due to extended-spectrum beta-lactamase- producing Escherichia coli and Klebsiella pneumoniae Clin Infect Dis 2001; 33: 1288-1294
18. Sanders WE, Sanders ChC. Enterobacter spp. Pathogens poised to flourish at turn of the century. Clin Microb Rev 1997; 10 (2): 220-241
19. Morris AJ. Susceptibility patterns of bacterial isolates from intensive care and haematology/oncology patients in New Zealand. New Zealand Medical Journal 1997; 110: 187-189
20. Eldeen AS, Araj GF, Thulesius O. A comparison of antibiotic consumption and bacterial resistance patterns in Kuwait and Sweden. AMPIS 1998; (Suppl 3):56-62
21. Muscato JJ, Wilbur DW, Stout JJ, Fahrlender RA. An evaluation of the susceptibility patterns of gram-negative organisms isolated in cancer center with aminoglycoside usage. Antimicrob Chemother 1991; 27: 1-7
22. Peetersmans WE, Bobbaers HJ. Amicacin as first-choice aminoglycoside in a medical intensive care unit: a one year bacteriological surveillance study. J Chemother 1996; 8 (1): 17-24
23. Kolář M, Urbánek K, Látal T. Antibiotic selective pressure and development of bacterial resistance. Int J Antimicrob Agents 2000; 17: 357-363
24. Gerding DN, Larson TA, Hughes RA, Weiler M, Shanholtzer C, Peterson LR. Aminoglycoside resistence and aminoglycoside usage: ten years of experience in one hospital. Antimicrob Agents Chemother 1991; 35 (7): 1284-1290
25. Mylotte JM. Gentamicin resistance among gram-negative bacillary blood isolates in a hospital with a long-term use of gentamicin. Arch Intern Med 1987; 147 (9): 1642-1644
26. Asensio A, Olivek A, Gonzales -Diego P. Outbreak of a multiresistant Klebsiella pneumoniae strain in an intensive care unit: antibiotic use as a risk factor for colonization and infection. Clin Infect Dis 2000; 30: 55-60
27. Mohr JF, Jones A, Zeichner-Ostrosky L, Wanger A, Tillotson G. Assotiation between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in a private, university-affiliated teaching hospital: a 8-year- experience: 1995-2002. Int J Antimicrob Agents 2004; 24:346-351
28. Patterson JE, Hardin TC, Kelly CA, Garcia RC, Jorgensen JH.Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2000; 21: 455-458
29. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002; 34: 634-640
30. Drlica K. The mutant selection window and antimicrobial resistance. J Antimicrob Chemother 2003; 52: 11-17
31. Li L, Lim CK: A novel large plasmid carrying multiple beta-lactam resistance genes isolated from a Klebsiella pneumoniae strain. J. Appl. Microbiol., 2000; 88: 1-14
32. Traub WH, Schwarze I, Bauer D. Nosocomial outbreak of cross-infection due to multiple-antibiotiv-resistant Klebsiella pneumoniae: characterization of the strain and antibiotic susceptibility studies. Chemotherapy 2000; 46: 1-14
33. Ardanuy C, Linares J, Dominguez MA, Hemandez-Alles S, Benedi VJ, Martinez-Martinez L. Outer membrane profiles of clonally related Klebsiella pneumoniae isolates from clinical samples and activities of cephalosporins and carbapenems. Antimicrob Agents Chemother 1998; 42: 1636-1640
34. Ahmad M, Urban C, Mariano N. Clinical characteristics and molecular epidemiology associated wih imipenem-resistant Klebsiella pneumoniae. Clin Infect Dis 1999; 29: 352-355.
35. Shah AA, Hasan F, Ahmed S, Hammed A: Characteristics, epidemiology and clinical importance of emerging strains of Gram-negative bacilli producing extended-spectrum β-lactamases. Research in Microbiology 2004; 155: 409-421
36. Zemelman C, Bello H, Domínguez M, Gonzales G, Mella S, Zemelman R. Activity of cefepime, cefotaxime, ceftazidime, and aztreonam against extended-spectrum- producing isolates of Klebsiella pneumoniae and Escherichia coli from Chilean hospitals. Diagnostic Microbiology and Infectious Disease 2001; 40: 41-43
37. Čermák P, Žabka L, Šlezarová P, Škrabková Z. Zlom ve vývoji rezistence Klebsiella pneumoniae a Pseudomonas aeruginosa izolovaných na jednotce intenzivní péče neurochirurgické kliniky FN v Hradci Králové v letech 1995-1999. Klin mikrobiol inf 2001; 7 (2). 43-46
38. Kolář M, Látal T. Implementation of a practical antibiotic policy in the Czech Republic. Infect Control Hosp Epidemiol 1999; 20: 440-443
39. Couper MR. Strategies for the rational use of antimicrobials. Clin Infect Dis 1997; 24 (Suppl 1): 154-156
40. White AC, Atmar RL, Wilson J et al. Effects on requiring prior authorization for selected antimicrobials: expenditures, susceptibilities and clinical outcomes. Clin Infect Dis 1997; 25: 230-239